Recent advances in medical management of benign prostatic hyperplasia: narrative review
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20253768Keywords:
LUTS, BPH, Treatment, Pharmacotherapy, Immunotherapy, Gene therapyAbstract
Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men, commonly linked with lower urinary tract symptoms (LUTS) such as frequency, urgency, nocturia, and weak urinary stream, all of which significantly impact quality of life. Pharmacological therapy remains the first-line management, yet conventional agents like alpha-1 blockers and 5-alpha reductase inhibitors (5-ARIs) often face challenges due to poor adherence, sexual side effects, and suboptimal symptom control. Given the progressive nature of BPH and its increasing prevalence in the elderly worldwide, including India, there is a need for more effective and better-tolerated treatment options. A comprehensive literature review was performed using PubMed, Cochrane Library, Wiley Online Library, Google Scholar, and ClinicalTrials.gov. Studies published between 2020 and 2025 were included to capture recent therapeutic innovations. References from selected articles were also cross-examined to ensure completeness. Pharmacological advances: While α-blockers and 5-ARIs remain standard, they inadequately target BPH’s multifactorial pathophysiology involving inflammation, hormonal imbalance, and increased smooth muscle tone. Emerging therapies include phosphodiesterase-5 (PDE-5) inhibitors, which relax prostate and bladder smooth muscle, improving both LUTS and erectile function; β3-adrenoceptor agonists for bladder storage symptoms; and gonadotropin-releasing hormone antagonists that reduce prostate volume without hormonal flare. Additionally, COX-2 inhibitors show promise in managing inflammation-driven LUTS such as nocturia. BPH represents a complex age-related condition beyond prostate enlargement. Although traditional therapies offer benefit, newer agents-targeting hormonal, inflammatory, and metabolic pathways-expand treatment options. Future care will rely on personalized, minimally invasive, and biologically informed strategies to enhance efficacy, safety, and patient quality of life.
Metrics
References
Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020;117(49):843-54. DOI: https://doi.org/10.3238/arztebl.2020.0843
Ng M, Leslie SW, Baradhi KM. Benign prostatic hyperplasia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2025.
O’Quin C, White KL, Campbell JR, Myers SH, Patil S, Chandler D, et al. Pharmacological approaches in managing symptomatic relief of benign prostatic hyperplasia: A comprehensive review. Cureus. 2023;15(12):e51314. DOI: https://doi.org/10.7759/cureus.51314
Haile ES, Sotimehin AE, Gill BC. Medical management of benign prostatic hyperplasia. Cleve Clin J Med. 2024;91(3):163-70. DOI: https://doi.org/10.3949/ccjm.91a.23027
Zhao J, Chen J, Sun G, Shen P, Zeng H. Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents. Cancer Biol Med. 2024;21(11):1012-32. DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0139
Ventura E, Gadaj A, Monteith G, Ripoche A, Healy J, Botrè F, et al. Development and validation of a semi-quantitative ultra-high-performance liquid chromatography-tandem mass spectrometry method for screening of selective androgen receptor modulators in urine. J Chromatogr A. 2019;1600:183-96.
Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17-25. DOI: https://doi.org/10.1016/j.clinthera.2007.01.018
Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study. Lancet Healthy Longev. 2019;3(11):e754-76.
Reddy M, Sarkar K, Sabnis R, Ramesh D, Therattil D, Goel A, et al. Algorithmic approach to benign prostatic hyperplasia: An Indian perspective. J Assoc Physicians India. 2024;72(7):e1-7.
Xu G, Dai G, Huang Z, Guan Q, Du C, Xu X. The etiology and pathogenesis of benign prostatic hyperplasia: The roles of sex hormones and anatomy. Res Rep Urol. 2024;16:205-14. DOI: https://doi.org/10.2147/RRU.S477396
Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia. [Updated 2024 Oct 20]. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2025.
Inamura S, Terada N. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options. Int J Urol. 2024;31(9):968-74. DOI: https://doi.org/10.1111/iju.15518
Yin S, Qiu Y. Prospective observational study of oxidative stress in the pathology of benign prostatic hyperplasia with bladder diverticulum. PLoS One. 2025;20(5):e0323677. DOI: https://doi.org/10.1371/journal.pone.0323677
Wei H, Zhu C, Huang Q, Yang J, Li Y-T, Zhang Y-G, et al. Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035. BMC Urol. 2025;25(1):34. DOI: https://doi.org/10.1186/s12894-025-01715-9
Schally AV, Theodoropoulos G, Sha W, Irving V, Medhi W. A 50-year journey in the development of treatment for benign prostatic hyperplasia. NPJ Aging. 2025;11(1):41. DOI: https://doi.org/10.1038/s41514-025-00231-2
Nachawati D, Leslie SW, Patel JB. Alpha-blockers. StatPearls Treasure Island. 2025.
Marberger M. MTOPS study. European urology supplements. Eu Urol. 2006;5:628-33. DOI: https://doi.org/10.1016/j.eursup.2006.05.002
Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by Dutasteride of prostate Cancer Events (REDUCE) trial. Urology. 2011;78(3):641-6. DOI: https://doi.org/10.1016/j.urology.2011.03.063
Lenfant L, Pinar U, Roupret M, Mozer P, Chartier-Kastler E, Seisen T. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients with Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol. 2023;209(2):314-24. DOI: https://doi.org/10.1097/JU.0000000000003077
Winograd J, Venishetty N, Codelia-Anjum A, Bhojani N, Elterman D, Zorn KC, et al. Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update. Expert Opin Emerg Drugs. 2024;29(3):205-17. DOI: https://doi.org/10.1080/14728214.2024.2363213
Sandhu JS, Vaughan ED Jr. Combination therapy for the pharmacological management of benign prostatic hyperplasia: Rationale and treatment options. Drugs Aging. 2005;22(11):901-12. DOI: https://doi.org/10.2165/00002512-200522110-00002
Jackson EM, Khooblall P, Lundy SD, Bajic P. A review of combined phosphodiesterase-5-inhibitors and α-blockers versus phosphodiesterase-5-inhibitors alone for lower urinary tract symptoms due to benign prostatic hyperplasia. Arab J Urol. 2024;22(1):13-23. DOI: https://doi.org/10.1080/2090598X.2023.2220627
Chen, X., Yang, S., He, Z, Zihao C, Xinling T, Yuxin L, et al. Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021. Sci Rep. 2025;15(1):5644. DOI: https://doi.org/10.1038/s41598-025-90229-3
Liu B, Wang X, Yang Z, Yin Z, Tang C, He Y, et al. A genetic study to identify pathogenic mechanisms and drug targets for benign prostatic hyperplasia: a multi-omics Mendelian randomization study. Sci Rep. 2024;14(1):23120. DOI: https://doi.org/10.1038/s41598-024-73466-w
Hennenberg M, Hu S, Tamalunas A, Stief CG. Genetic predisposition to benign prostatic hyperplasia: Where do we stand? Eur Urol Open Sci. 2024;70:154-7. DOI: https://doi.org/10.1016/j.euros.2024.10.012
Hassan MS, Irfan HM, Alamgeer, Sarwar M, Jabbar Z, Nawaz S. Emerging therapeutic frontiers in prostate health: Novel molecular targets and classical pathways in comparison with BPH and prostate cancer. Crit Rev Oncol Hematol. 2025;206(104590):104590. DOI: https://doi.org/10.1016/j.critrevonc.2024.104590
Wang Y, Wang J, Liu J, Zhu H. Immune-related diagnostic markers for benign prostatic hyperplasia and their potential as drug targets. Front Immunol. 2024;15:1516362. DOI: https://doi.org/10.3389/fimmu.2024.1516362
Vickman RE, Franco OE, Hayward SW. Could TNF-antagonists be a novel treatment strategy for BPH patients? Cell Stress. 2022;6(6):65-7. DOI: https://doi.org/10.15698/cst2022.06.268
Ückert S, Kedia GT, Tsikas D, Simon A, Bannowsky A, Kuczyk MA. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate. World J Urol. 2020;38(6):1423-35. DOI: https://doi.org/10.1007/s00345-019-02933-1
Eri LM, Tveter KJ. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol. 1993;150(2 Pt 1):359-64. DOI: https://doi.org/10.1016/S0022-5347(17)35483-6
Soltani S, Ghorbani H, Tavakkoli M, Mottaghi M, Emadzadeh M, Aghaee A. Effects of Leuprolide as an adjunctive treatment of benign Prostatic Hyperplasia, a randomized controlled clinical trial. Arch Pharma Pract. 2020;11(S4):75-9.
Sun Y, Xie L, Xu T, Jakobsen JS, Han W, Sørensen PS, et al. Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China. Asian J Urol. 2020;7(3):301-8. DOI: https://doi.org/10.1016/j.ajur.2019.09.003
Mirzayans R, Murray D. Do TUNEL and other apoptosis assays detect cell death in preclinical studies? Int J Mol Sci. 2020;21(23):9090. DOI: https://doi.org/10.3390/ijms21239090
Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: A prospective, randomized, double-blind, placebo-controlled study. Urology. 2008;72(4):813-6. DOI: https://doi.org/10.1016/j.urology.2008.04.069
Shin TJ, Ha JY, Kwon SY, Park DJ, Kim JH, Lee SW, et al. A randomized, active-controlled, multicenter, phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia. Prostate Int. 2025;13(2):81-9. DOI: https://doi.org/10.1016/j.prnil.2024.10.001
Vinarov A, Pushkar D, Spivak L. Pd24-03 efficacy and safety of afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: A multicenter, double-blind, placebo-controlled, randomized clinical trial. J Urol. 2019;201(4):427-35. DOI: https://doi.org/10.1097/01.JU.0000555930.36243.a1
Enemchukwu EA, Kalota S, Robertson K, Ge S, Lu J, Badger H, et al. Gene therapy with URO-902 (pVAX/ hSlo) for the treatment of female patients with overactive bladder and urge urinary incontinence: Safety and efficacy from a randomized phase 2a trial. J Urol. 2025;213(4):417-27. DOI: https://doi.org/10.1097/JU.0000000000004373
Chung KJ, Kim JW, Min GE, Park CH, Son H, Jeong H. Effects of a 12-week open-label exercise program on lower urinary tract symptoms and quality of life in elderly men. Int Neurourol J. 2017;21(2):97-101. DOI: https://doi.org/10.5213/inj.1734928.464
Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011;59(5):747-54. DOI: https://doi.org/10.1016/j.eururo.2010.11.024
Ventura E, Gadaj A, Monteith G, Ripoche A, Healy J, Botrè F, et al. Development and validation of a semi-quantitative ultra-high-performance liquid chromatography-tandem mass spectrometry method for screening of selective androgen receptor modulators in urine. J Chromatogr A. 2019;1600:183-96. DOI: https://doi.org/10.1016/j.chroma.2019.04.050
Pencina KM, Burnett AL, Storer TW, Guo W, Li Z, Kibel AS, et al. A selective androgen receptor modulator (OPK-88004) in prostate cancer survivors: A randomized trial. J Clin Endocrinol Metab. 2021;106(8):2171-86. DOI: https://doi.org/10.1210/clinem/dgab361
Shinghal R, Barnes A, Mahar KM, Stier B, Giancaterino L, Condreay LD, et al. Safety and efficacy of Epelsiban in the treatment of men with premature ejaculation: A randomized, double-blind, placebo-controlled, fixed-dose study. J Sex Med. 2013;10(10):2506-17. DOI: https://doi.org/10.1111/jsm.12272
Darakhshan S, Pour AB. Tranilast: A review of its therapeutic applications. Pharmacol Res. 2015;91:15-28. DOI: https://doi.org/10.1016/j.phrs.2014.10.009
Saadat H, Bhojani N, Elterman D, Chughtai B. Vibegron for overactive bladder in men with benign prostatic hyperplasia/obstruction: insights from the COURAGE trial. Transl Androl Urol. 2025;14(4):888-92. DOI: https://doi.org/10.21037/tau-2024-759
Patel SB, Patel V, Captan H. Effect of enalapril and losartan on testosterone-induced benign prostatic hyperplasia in rats. FASEB J. 2013;27(S1):1170.4. DOI: https://doi.org/10.1096/fasebj.27.1_supplement.1170.4
Mostafa F, Mantawy EM, Azab SS, Abdel-Baky NA. The angiotensin converting enzyme inhibitor captopril attenuates testosterone-induced benign prostatic hyperplasia in rats: A mechanistic approach. Eur J Pharmacol. 2019;865:172729. DOI: https://doi.org/10.1016/j.ejphar.2019.172729
Fujimoto K, Hirao Y, Masumori N, Tsukamoto T, et al. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: A retrospective multi-institutional study. Int J Urol. 2006;13(5):543-9. DOI: https://doi.org/10.1111/j.1442-2042.2006.01343.x
Ruijter E, Maarschalk KVDV. Use of etonogestrel for benign prostate hyperplasia (BPH). 2009. Available at: https://patents.google.com/patent/WO2009101182A1/en. Acceded on 12 June 2025.
Chughtai B, Dunphy C, Lee R, Te AE, Kaplan SA. Randomized, double-blind, placebo-controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Can J Urol. 2014;21(2):7217-21.
Marberger M, Chartier-Kastler E, Egerdie B, Lee M. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63(3):496-503. DOI: https://doi.org/10.1016/j.eururo.2012.10.005
Antoniou V, Gauhar V, Modi S, Somani BK. Role of phytotherapy in the management of BPH: A summary of the literature. J Clin Med. 2023;12(5):1899. DOI: https://doi.org/10.3390/jcm12051899
Kang TW, Kim SJ, Kim MH, Jung JH. Beta-3 adrenoreceptor agonist for the management of lower urinary tract symptoms in men with benign prostatic hyperplasia: A systematic review. Int Neurourol J. 2021;25(3):182-91. DOI: https://doi.org/10.5213/inj.2142068.034
Salisbury BH, Leslie SW, Tadi P. 5α-reductase inhibitors. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2025.
Elterman DS, Chughtai B, Lee RK, Te AE, Kaplan SA. Update on phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Rev Urol. 2012;14(3-4):79-86.
Ingelman-Sundberg M, Nebert DW, Lauschke VM. Emerging trends in pharmacogenomics: From common variant associations toward comprehensive genomic profiling. Hum Genomics. 2023;17:105. DOI: https://doi.org/10.1186/s40246-023-00554-9
Downloads
Published
How to Cite
Issue
Section
